Pfizer announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly
The EC’s approval follows a positive opinion in October from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). Earlier this year, Agilis received Orphan Drug
Pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that may play a role in depression. Massachusetts General Hospital (MGH) Department of Psychiatry executive vice
Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and address an unmet medical need. The designation enables
The Natrix Protein A platform is expected to pave the way for a new generation of more flexible, highly-productive single-use based biologics production facilities for both batch and
Risankizumab is being evaluated in immunological disorders, including Crohn's disease, psoriasis, psoriatic arthritis and asthma. Risankizumab is an investigational treatment that is part of a collaboration between Boehringer
Evotec announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile
The expansion is in response to customer demand for medical device manufacturing, especially in the area of diabetes, and represents West's most recent investment in Ireland, where the
The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, France,
Background to the acquisition This acquisition is consistent with Ergomed’s stated strategy to grow its existing, profitable services businesses both organically and through bolt-on acquisitions. The transaction will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.